Magnetoencephalography in Psychosis Program
Launched by DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE · May 11, 2025
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Schizophrenia is a common and severe mental illness affecting millions of people worldwide. With a lifetime prevalence of about 1%, it is estimated to generate annual costs of $10 billion in Canada alone, with cognitive and functional impairments as major contributors. One of the main and most debilitating symptoms of schizophrenia is related to the disorganization and impoverishment of speech, also known as Formal Thought Disorder (FTD). The presence of linguistic disorganization and impoverishment seen in FTD is recognized as an early marker of disease; it can be present in otherwise heal...
Gender
ALL
Eligibility criteria
- 1. Patients:
- Inclusion Criteria:
- • Clinical diagnosis of schizophrenia as per DSM-5 criteria.
- • Aged between 18 and 50 years.
- • In a stable phase of the illness (no change in Global Functioning \> 10 units within 1 month before the MEG scan assessed using the Global Assessment of Functioning Scale).
- Exclusion Criteria:
- • Inability to speak English or French.
- • History of head trauma, major neurological disorders (e.g., epilepsy), somatic disorders with neurological complaints (e.g., multiple sclerosis), or intellectual disabilities.
- • Diagnosis of substance use disorder (current or within the last year) as per DSM-5.
- • Unsuitable for MRI due to safety concerns (e.g., metal in the body, pregnancy, tinnitus).
- • 2. Healthy Controls
- Inclusion Criteria:
- • Healthy volunteers aged between 18 and 50 years.
- • Matched to patients for age (within 2 years), sex, and parental occupational status (rated by NS-SEC).
- Exclusion Criteria:
- • Inability to speak English or French.
- • History of head trauma, major neurological disorders (e.g., epilepsy), somatic disorders with neurological complaints (e.g., multiple sclerosis), or intellectual disabilities.
- • Diagnosis of substance use disorder (current or within the last year) as per DSM-5.
- • Personal or family history of psychotic disorder.
- • Unsuitable for MRI due to safety concerns (e.g., metal in the body, pregnancy, tinnitus).
About Douglas Mental Health University Institute
The Douglas Mental Health University Institute is a leading research and clinical facility dedicated to advancing the understanding and treatment of mental health disorders. Affiliated with McGill University, the institute integrates cutting-edge scientific research with clinical practice to foster innovation in mental health care. Focused on collaborative and interdisciplinary approaches, the Douglas Institute conducts a range of clinical trials aimed at developing new therapeutic strategies and improving patient outcomes. Its commitment to excellence in research, education, and community service positions it as a vital contributor to the field of mental health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Lena Palaniyappan, MD, PhD
Principal Investigator
Douglas Mental Health University Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported